Symphogen A/S Advances Sym015 into Clinical Development Using Selexis SGE (Selexis Genetic Elements)
Geneva, Switzerland, 29 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, has progressed its Sym015 clinical candidate into a Phase 1 dose escalation trial in patients with solid tumors. Symphogen relied upon Selexis SGE® (Selexis Genetic Elements) to facilitate the rapid, stable, and cost-effective expression of Sym015, which is a multi-targeting monoclonal antibody (MAb) mixture that targets the MET receptor.
The proto-oncogene c-MET, also called MET, has been recognized as an important mediator of uncontrolled growth of solid tumors. Research has shown that driver mutations that result in activation of the MET receptor tyrosine kinase (RTK) are associated with a wide range of human malignancies including cancers of the kidney, liver, stomach, breast, and brain.
Selexis SGEs are the foundation of the SUREtechnology Platform™. SGEs are unique epigenetic DNA-based elements that control the dynamic organization of chromatin in all mammalian cells and allow for higher and more stable expression of recombinant proteins.
“We are pleased that the power of our Selexis Genetic Elements helped Symphogen efficiently produce their next-generation antibody candidate, Sym015, and move it rapidly into clinical development,” said Igor Fisch, PhD, chief executive officer and chairman of Selexis. “The goal of our proprietary technology is to help our biopharmaceutical partners advance their discovery development programs into clinical trials and, ultimately, biologics manufacturing, offering patients new and improved treatment options.”
· Web www.selexis.com
· LinkedIn www.linkedin.com/company/selexis-sa
· Twitter www.twitter.com/SelexisSA
· Facebook www.facebook.com/SelexisSA
Contact details
-
- Sarah Martin-Tyrrell
-
KBI Biopharma Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
Related topics
Related news
KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Monoclonal Antibody Candidate
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Phar...
Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges.
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and M...
KBI Biopharma, Inc. (KBI Biopharma), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform, that allows for optim...